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ABSTRACT
This article discusses the recently published
EMPA-REG OUTCOME trial, which assessed
cardiovascular outcomes with empagliflozin
therapy in persons with type 2 diabetes mellitus
and coexisting cardiovascular disease. The article
describes the background and challenges of
modern cardiovascular outcome trials, points out
the strengths of the EMPA-REGOUTCOME study,
and places the results in perspective. It highlights
the significant impact that these results will have
on cardiovascular preventive pharmacotherapy,
andonfuturedrugdevelopment indiabetes.At the
same time, it reminds readers of the limitations of
the results, and lists the questions raised by, or left
unanswered by, the trial.
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INTRODUCTION
The EMPA-REG OUTCOME trial
(ClinicalTrials.gov identifier, NCT01131676)
recently announced the effects of
empagliflozin on the cardiovascular outcomes
(CVO) and mortality in persons with type 2
diabetes mellitus (T2DM) [1]. In this seminal
CVO trial (CVOT), 7020 patients with T2DM
with coexisting cardiovascular disease (CVD;
myocardial infarction [MI], stroke, or peripheral
arterial disease) were randomized to either
10 mg empagliflozin, 25 mg empagliflozin, or
placebo, over and above standard of care. The
primary composite outcome was a total of three
endpoints (death from CV causes, non-fatal MI,
and non-fatal stroke), while the key secondary
endpoint included a fourth endpoint—
hospitalization for unstable angina—in
addition to the composite primary endpoint [1].
The results of this study revealed a
statistically significant reduction in the
primary endpoint with empagliflozin use
(10.5% in the empagliflozin group vs. 12.1%
in the placebo group; hazard ratio 0.86; relative
risk reduction (RRR) 14%, 95% confidence
interval 0.74–0.99; P = 0.04). Similarly, a RRR
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reduction is noted in death from CV causes
(RRR 38%; 3.7% vs. 5.9%), hospitalization for
heart failure (RRR 35%; 2.7% vs. 4.1%), and
all-cause death (RRR 32%; 5.7% vs. 8.3%).
However, the difference in rates of non-fatal
MI and non-fatal stroke did not reach statistical
significance.
This article is based on previously conducted
studies and does not involve any new studies of




Earlier trials have also reported CVO with
various glucose-lowering medications. The
University Group Diabetes Program (UGDP)
study, published nearly half a century ago,
highlighted the negative effects of tolbutamide
on CV health [2]. The United Kingdom
Prospective Diabetes Study (UKPDS), a large
study with multiple arms, unearthed the
beneficial impact of metformin in contrast to
other drugs such as chlorpropamide in
improving CVO in T2DM [3]. The
STOP-NIDDM trial, breaking new ground,
suggested CVO improvement when acarbose
was administered to persons with impaired
glucose tolerance [4]. Similarly, the PROActive
trial on pioglitazone reported a reduction in the
composite of all-cause mortality, non-fatal MI,
and stroke in patients with T2DM who have a
high risk of macrovascular events [5]. However,
all of these studies were not designed as a
CVOT, and their primary aim was to assess
glucose-lowering efficacy rather than
improvement in CV health.
Advances in the understanding of the
interlink between diabetes and CV disease
(CVD), an appreciation of the need to improve
CVO in diabetes care, and the realization that
effective glucose-lowering drugs could end up
worsening CVO (e.g., muraglitazar [6]), have led
to a mandatory requirement for CVOTs in
anti-diabetic drugs pending regulatory
approval.
It then became imperative for all newly
developed glucose-lowering molecules to
undergo CV safety analysis by performing a
CVOT. The first drug to report such an analysis,
after institution of new regulatory requirements,
was quick-release bromocriptine, which
demonstrated CV safety in a trial which
recruited 3070 subjects for a mean follow up of
52 weeks [7]. Since then, various data on
dipeptidyl-peptidase 4 inhibitors [8–10] and
insulins [11] have been published from
large-scale CVOTs which have suggested their
CV safety.
While these CVOTs follow similar trial
designs and protocols, subtle variations are
present [8–11]. Differences in inclusion/
exclusion criteria, the duration of follow up,
and the choice of primary/secondary endpoints
can be easily discerned. Though debate around
the validity of various trial designs is never
ending, there is broad consensus that modern
CVOTs are well designed and have good
reliability. All recent CVOTs have been
designed to demonstrate CV safety
(non-inferiority), rather than superiority, as
requested by regulators. This fact should be




Over the past few decades the standard of care for
CVpreventionhas improvedmarkedly across the
globe. Use of medical interventions such as
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aspirin, statins, angiotensin-converting-enzyme
inhibitors (ACEi), angiotensin receptor blockers
(ARBs), and beta blockers has helped to enhance
CVO, especially in persons with T2DM. Though
widespread use of these standard of care drugs
alloweasier demonstrationofCVsafety, their use
makes it difficult for a new add-on therapy to
demonstrate improvement in CVO.
EMPAGLIFLOZIN: BETTER BENEFIT
This is exactly what empagliflozin has achieved.
In a high-risk cohort of subjects, with over 75%
usage of statins, over 80% use of ACEi/ARBs,
and over 60% beta-blocker therapy,
administration of empagliflozin was able to
demonstrate added benefit in terms of CVO
[1]. This speaks for the strength of the molecule
being studied, as well as the robust quality of
trial methodology followed by the authors of
the study. Inclusion of a wide variety of
high-risk subjects, from 42 different
nationalities, enhances the global applicability
of these results.
The benefits of empagliflozin were noted
early on in the EMPA-REG OUTCOME trial, and
continued throughout the study [1]. This
finding makes empagliflozin stand apart from
other CVD preventive drugs, such as statins and
ramipril, which demonstrated a CV benefit after
a longer duration of therapy. Whether this
means that empagliflozin is an effective drug
for secondary prevention of CVD, that is, the
prevention of progression of CVD to death is
open to debate. Detractors point to the lack of
statistical significance noted with respect to
occurrence of non-fatal MI and stroke.
However, this finding may be thought to
reinforce the ‘‘preventive power’’ of
empagliflozin: It may even be used in tertiary
CVD prevention, as it helps improve outcomes
in persons with T2DM who experience an MI or
stroke, ensuring that they survive the acute
illness. Thus, empagliflozin may be useful for
tertiary prevention, rather than secondary
prevention, of CVD. The number needed to
treat, (for all-cause mortality), which was 39 for
empagliflozin over a period of 3 years, is much
lower than that reported for other drugs,
including ramipril and simvastatin [12, 13].
The highly significant benefit of
empagliflozin (P = 0.002) in preventing
hospitalization for heart failure raises hope for
its use in this clinical situation [1]. This finding
is especially welcome considering the
controversy related to the increased risk of
heart failure hospitalization with other
glucose-lowering therapies [14]. Empagliflozin,
therefore, gets evidence-backed justification for
use not only as a glucose-lowering therapy, but
also raises hope for its potential as adjunctive
therapy for CVD prevention (Table 1).
EMPAGLIFLOZIN: EXPANDING
BOUNDARIES
The EMPA-REG OUTCOME results should be
carefully interpreted to assess their impact on
diabetes care and outcomes. While the findings
for different subsets of patients need to be
studied separately, the EMPA-REG OUTCOME
study also throws up a few interesting questions
(Table 1). Will these beneficial results be
relevant to persons with T2DM and low CV
risk, or to persons with type 1 diabetes mellitus?
Whether the findings of empagliflozin can be
extrapolated to other sodium-glucose
co-transporter 2 inhibitors (SGLT2i) are open
to discussion. CVOTs are underway for both
canagliflozin and dapagliflozin, and their results
will decide whether the CV benefits of
empagliflozin are a class effect or not [15].
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It is also uncertain if empagliflozin can be
initiated, or continue to be used, in acute
coronary settings, including unstable angina,
MI, and heart failure. However, while
translating CVOT evidence to practice one
should not lose sight of good clinical sense.
SGLT2i biology and pharmacology should be
understood in detail before prescribing SGLT2i
[16]. This therapy should be accompanied by
appropriate medication counseling and should
not be prescribed to persons at risk of
ketoacidosis or recurrent genital infections [17].
SUMMARY
While the EMPA-REG OUTCOME study
findings should be interpreted carefully to
assess their impact on diabetes care and
outcomes, the results go far beyond proving
the superiority of empagliflozin in improving
CVO [1]. The seminal importance of these
findings will ensure that this trial acts as a
milestone in the fields of diabetology and CV
medicine.
The EMPA-REG OUTCOME study raises the
bar for future glucose-lowering drugs. It will not
now suffice to demonstrate CV neutrality or CV
safety. Rather, unequivocal evidence of CV
benefits will be required. Such a development
will help improve not only CVO, but also
diabetes outcomes overall. The EMPA-REG
OUTCOME study may be just a small step for
empagliflozin, but is a giant leap for diabetes
care.
ACKNOWLEDGMENTS
No funding or sponsorship was received for
publication of this article. The named author
meets the International Committee of Medical
Journal Editors (ICMJE) criteria for authorship
for this manuscript, takes responsibility for the
integrity of the work as a whole, and has given
final approval for the version to be published.
Table 1 Impact of EMPA-REG OUTCOME study [1]
Strengths
Robust methodology/clinical design
Multinational coverage (42 countries)
Applicability across age, gender, CV phenotype
Clinically relevant inclusion/exclusion criteria
Clear-cut answers from straightforward statistical
analysis
Positive answers
Empagliﬂozin is safe in high-risk CV patients with
T2DM
Empagliﬂozin improves CV outcomes in high-risk CV
patients with T2DM
Empagliﬂozin can be used safely in combination with
other vascular-tropic drugs over an extended period of
time
Empagliﬂozin can be used for prevention of CVD
Empagliﬂozin does not increase the risk of diabetic
ketoacidosis or bone fractures
Unanswered questions
Is the beneﬁcial effect of empagliﬂozin a class effect, or
a property unique to this molecule?
What are the mechanisms that account for the
potential of empagliﬂozin to reduce CV outcomes?
Is the beneﬁcial CV effect of empagliﬂozin relevant to
patients with T2DM and low CV risk, and to patients
with type 1 diabetes mellitus?
Can empagliﬂozin be prescribed in acute coronary
settings?
Can empagliﬂozin be considered an adjuvant
preventive therapy for CVD?
CV cardiovascular, CVD cardiovascular disease, T2DM type
2 diabetes mellitus
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